💡 律咖编者按： 本文由律咖网社群读者 ChangXi 投稿分享。 为了方便大家阅读，律咖网编辑 JingJing（微信：lvga2015）对原文进行了细致的逻辑润色与合规性整理。希望能给正在 巴基斯坦 创业路上的你带来真实的参考。

I’m ChangXi — a 46-year-old woman from Dalian, trained in medical imaging technology, now trying to register a trademark for thermal recycling equipment in Pakistan. I didn’t come here for pharma. But in Faisalabad, every business conversation eventually leads to compliance — and every compliance question circles back to signatures.

The question I kept hearing: “Can you use an electronic signature on your drug registration documents?”

At first, I thought it was a technical detail. Then I realized: it’s a proxy for trust. In markets where paper trails are still king, the absence of a wet ink signature isn’t just inconvenient — it’s a red flag. But things are shifting. Slowly.

Here’s what I’ve learned by asking too many questions, sitting in too many waiting rooms, and listening to local consultants who don’t get paid unless you get approved.

One: Surface Phenomenon

In Faisalabad’s pharmaceutical regulatory ecosystem, the Drug Regulatory Authority of Pakistan (DRAP) requires physical signatures on nearly all submissions — from product registration applications to Good Manufacturing Practice (GMP) compliance forms. This is the official rule. It’s printed on their website. It’s repeated in every orientation session.

But the reality? Most serious local pharma firms — the ones with export ambitions — are already using digital tools. Not for the official submission, but for internal approvals, vendor contracts, and audit trails. I spoke with a compliance officer at a mid-sized Faisalabad manufacturer who showed me his team’s encrypted e-signature workflow on DocuSign. “We send it to our head office in Lahore,” he said. “Then we print, sign, scan, and submit the PDF to DRAP.”

So the surface phenomenon is: Official policy requires wet ink. But in practice, digital signatures are already embedded in the workflow — just not at the final submission point.

The misunderstanding? That digital = invalid. The truth? Digital = preparatory.

Two: Hidden Variables

There are three hidden variables nobody talks about in public meetings.

1. The “Chain of Custody” Fear
DRAP’s internal review teams are trained to spot inconsistencies. If a document has an electronic signature but no notarized cover letter or physical stamp from the company’s registered office, it triggers a “document integrity” query. In rural or semi-urban offices — like those in Faisalabad — staff still rely on visual cues: ink, stamp, signature alignment. A digital signature without a physical anchor feels “unverified,” even if legally defensible.

2. The Language Gap
Most DRAP forms are in Urdu. E-signature platforms like DocuSign or Adobe Sign default to English. If the system generates a certificate of authenticity in English, but the DRAP officer only reads Urdu, the document becomes a “foreign object.” No one says it outright — but they delay it. Until you print, sign, and stamp.

3. The “We’ve Always Done It This Way” Threshold
I asked a former DRAP inspector (now a compliance consultant) why they resist e-signatures. He laughed and said: “If I approve a digitally signed document, and something goes wrong five years later, who do I blame? The system? The vendor? Or me?” He didn’t say it was illegal. He said it was risky for his career.

The hidden variable isn’t law. It’s liability culture.

Three: Institutional Logic

Pakistan’s regulatory system isn’t anti-digital. It’s anti-uncertainty.

The country’s legal framework does recognize electronic signatures under the Electronic Transactions Ordinance, 2002 — which aligns with UNCITRAL Model Law. But implementation is fragmented. DRAP operates under the Ministry of National Health Services, which lacks centralized IT infrastructure. Each regional office — Faisalabad, Lahore, Karachi — has its own internal protocols.

What’s more, Pakistan’s international trade partners — especially the U.S. — are now probing for forced labor in exports, including pharma goods. That means the government is under pressure to show “traceability,” “auditability,” and “transparency.” Ironically, digital signatures would help. But until DRAP integrates with a national digital identity system (like NADRA’s digital ID), they won’t risk changing their process.

The institutional logic?
Stability > Innovation.
Process > Speed.
Paper = Accountability.

Digital tools are tolerated as internal aids. But the final submission? It must feel tangible. Because in a system where corruption rumors linger, the physical signature is the last line of defense — for both the regulator and the applicant.

Four: Entrepreneur’s Perspective

As a foreign entrepreneur — not in pharma, but trying to navigate its ecosystem — here’s what I do:

1. Never assume e-signatures are accepted.
Assume they are not. Then build a workaround.
→ Use digital tools to streamline your internal approvals.
→ Print, sign, stamp, scan.
→ Submit the PDF with a cover letter stating: “This document has been digitally prepared and authenticated internally, and signed in original for regulatory submission.”

2. Build a paper trail with local partners.
I partnered with a Faisalabad-based compliance consultant who has 17 years in DRAP submissions. He doesn’t use e-signatures either. But he has a stamp. And a signature. And a notebook with dates, names, and receipt numbers. That notebook is his credibility. You need one too.

3. Ask for the “Sample Submission Package.”
Not the policy document. The actual example.
I asked a consultant: “Show me a recent approved registration with an electronic signature.” He looked at me like I’d asked to fly.
Then he pulled out a binder. Every page had a wet signature.
“See? This is what they accept.”

4. Don’t push. Wait for the system to catch up.
I heard in a LinkedIn group for South Asian pharma exporters that DRAP is piloting a digital portal for GMP renewals — expected in Q3 2026.
Don’t be the first to test it. Be the second.
By then, the template will be clear. The staff will be trained.
The risk drops. The cost drops. The approval rate goes up.

❓ FAQ

Q1: Can I use DocuSign or Adobe Sign to sign my DRAP drug registration form?

A:

  • Step 1: Use e-signature tools internally for approvals and audit trails.
  • Step 2: Print the final document.
  • Step 3: Sign with ink, affix company stamp, date.
  • Step 4: Scan and submit as PDF.
  • Step 5: Include a cover letter: “This document was digitally prepared and authenticated by [Company Name], with original wet ink signature attached.”
  • Key Points:
    • Never submit only a digital signature.
    • Always include physical signature + stamp.
    • Keep original signed copies for 10 years — DRAP may request them.

Q2: Is there a government-approved e-signature platform for pharmaceutical compliance?

A:

  • Step 1: Visit the National Database and Registration Authority (NADRA) portal: nadra.gov.pk.
  • Step 2: Check for “Digital Signature Certificate” issuance — available for businesses.
  • Step 3: Use NADRA-certified e-signature providers (e.g., Digilocker, PKI-based systems).
  • Step 4: Submit the NADRA certificate alongside your DRAP application as proof of digital identity.
  • Key Points:
    • NADRA certificates are legally recognized under the Electronic Transactions Ordinance.
    • DRAP does not yet accept them alone — but they strengthen credibility.
    • Use them as supporting evidence, not the primary signature.

Q3: What if my foreign company doesn’t have a physical stamp or local director in Pakistan?

A:

  • Step 1: Appoint a local agent or compliance liaison with a registered office in Faisalabad or Lahore.
  • Step 2: Have them sign and stamp on your behalf — with a notarized Power of Attorney (PoA).
  • Step 3: Attach the PoA to your DRAP submission.
  • Step 4: Use a Pakistani notary public to verify the agent’s authority.
  • Key Points:
    • Foreign companies cannot submit directly without a local representative.
    • The agent’s signature + stamp = legal standing.
    • You can outsource this — many Faisalabad firms offer “compliance agent” services for $150–300/month.

Final Thoughts

I came to Pakistan to sell thermal recycling machines. I didn’t plan to become an expert in pharmaceutical compliance. But here I am — because in emerging markets, the real bottleneck isn’t technology. It’s trust.

E-signatures are coming. But they won’t replace ink until the system feels safe enough to let go.

Until then:

  • Print. Sign. Stamp. Scan.
  • Build relationships with local agents.
  • Follow the paper trail.
  • Be patient.

The system moves slowly. But when it moves, it moves for everyone.

If you’re also navigating compliance in Faisalabad — or anywhere in Pakistan — I’d love to hear how you’re handling signatures, documents, or vendor approvals.
We’re a small group of real entrepreneurs on this path — no consultants, no sales pitches. Just shared experience.

Join our cross-border startup discussion group — or reach out to JingJing (微信: lvga2015) if you have questions about DRAP, local agents, or document workflows.

We don’t promise approvals. But we can help you avoid the mistakes we made.

🔸 延伸阅读

🔸 Pakistan among 60 countries facing US forced labour investigations
🗞️ 来源: Dawn – 📅 2026-03-13
🔗 阅读原文

🔸 Pakistan PM Sharif Meets Saudi Crown Prince, Assures Full Support Amid West Asia Tensions
🗞️ 来源: ABP Live – 📅 2026-03-13
🔗 阅读原文

🔸 BCCI breaks silence on Pakistan cricketer Abrar Ahmed’s Hundred deal with Sunrisers Leeds
🗞️ 来源: Moneycontrol – 📅 2026-03-13
🔗 阅读原文

📌 免责声明

请知悉：律咖网（Lvga.com）是跨境创业公开信息与内容分享平台，不提供法律、税务、会计或合规服务。
本文内容基于公开资料，并由人工编辑与 AI 工具协助整理，仅供信息参考之用，不构成任何法律、投资、移民或商业决策建议。
政策可能随时间变化，请以官方渠道与当地持牌专业人士意见为准。
如内容有需要修订之处，欢迎随时与我联系。